Profit soared at Pfizer in the third quarter, a sign President Trump’s crusade against high drug prices has yet to significantly affect the world’s largest pharmaceutical company.

Net income rose 45 percent to $4.1 billion, or 69 cents a share, though revenue at the New York City-based drugmaker was little changed at $13.3 billion in the three months through September.

Pfizer lowered the high end of its full-year sales guidance to $53.7 billion from $55 billion, citing a slowdown in its Essential Health unit. Sales in the division, which covers sterile injectables and biosimilars, fell 4 percent, driven by a 14 percent decline in legacy products. Several of Pfizer’s most popular drugs, like Viagra, recently lost exclusivity and are facing sales pressure from generic rivals.

The company is “well-positioned to develop and commercialize” new treatments, outgoing Chief Executive Officer Ian Read said, as well as maximize the opportunity of in-market products, advance key pipeline programs, and accelerate emerging-market growth.

Pfizer's stock dropped 1 percent to $42.76 in pre-market trading in New York.

Trump announced earlier this month his administration would seek to tie the reimbursement for drugs covered under Medicare Part B to international prices, which are often lower than in the U.S.

His predecessor, Barack Obama, also attempted to advance a Part B-related proposal that would have lowered the reimbursement amount that Medicare pays to drug companies. It was met with significant pushback from pharmaceutical companies, including Pfizer, that said the plan was flawed and “likely to have significant unintended consequences for patients facing serious and life-threatening diseases.”

Read hopes the administration will rethink its proposal, which he claimed "imports price controls from abroad into the U.S."

"I don’t think its in the best interest of patients," he said on Pfizer's earnings call.

Read previously claimed the administration would take steps this year to reform the drug rebate system, an action that could target the business model of middlemen pharmacy benefit managers. No such proposal has been made public, but it "continues to be a point of interest for the administration," Read said.

"It is the most effective way the administration can lower prices for patients at the point of purchase," he told investors.

After hiking the price of several of its drugs earlier this year, Trump tweeted that Pfizer "should be ashamed," prompting the company to postpone the cost increases until the end of 2018 or the administration's drug pricing blueprint takes effect.

When asked whether Pfizer intends to raise costs in January -- the month that pharmaceutical companies typically institute significant price increases -- Read hedged.

"We will look at our pricing situation in January and take decision based on what the competitive set is and what our value proposition is in the new marketplace," he said.